Cargando…
Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
INTRODUCTION: MDD represents a significant burden worldwide, and while a number of approved treatments exist, there are high rates of treatment resistance and refractoriness. Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist, is a novel, rapid-acting antidepressant, however the mechanism...
Autores principales: | Irwin, Madison N., VandenBerg, Amy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
College of Psychiatric & Neurologic Pharmacists
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120982/ https://www.ncbi.nlm.nih.gov/pubmed/34026396 http://dx.doi.org/10.9740/mhc.2021.05.200 |
Ejemplares similares
-
Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?
por: Peckham, Alyssa M., et al.
Publicado: (2018) -
Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
por: Diefenderfer, Lauren A., et al.
Publicado: (2018) -
Pharmacokinetic characteristics of antiepileptic drugs (AEDs)
por: Marvanova, Marketa
Publicado: (2016) -
A review of significant pharmacokinetic drug interactions with antidepressants and their management
por: Hoffelt, Charity, et al.
Publicado: (2016) -
Pharmacogenetics of antiepileptic drugs: A brief review
por: Parker, D., et al.
Publicado: (2016)